Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis

Table 1 Values of overall survival reported in the 7 randomized controlled trials

Ref.	Year ofpublication	Patients		Control arm				Experimental arm				P value
		Age1(yr)	Race	Treatment	N	MedianOS(mo)	SE2(mo)	Treatment	N	MedianOS(mo)	SE2(mo)
3Kang et al[4]	2012	56	Korean	BSC	69	3.8	0.36	Docetaxel	66	5.2	0.71	0.07
Hironaka et al[3]	2011	65	Japanese	Irinotecan	111	8.4	0.56	Paclitaxel	108	9.4	0.59	0.22
Thuss- Patience et al[10]	2011	56	-	BSC	19	2.4	0.82	Irinotecan	21	4	0.99	0.22
Ford et al[1]	2014	65 (34-84)	English	BSC	84	3.6	0.28	Docetaxel	84	5.2	0.46	0.003
Ohtsu et al[9]	2013	62 (22-86)	Various (white, Asian, black or other)	BSC	217	4.3	0.43	Everolimus	439	5.4	0.31	0.039
Fuchs et al[2]	2014	60 (51-69)	Various (white, Asian, black or other)	BSC	117	3.8	1.38	Ramucirumab	238	5.2	1.94	0.65
Wilke et al[11]	2014	61 (24-83)	Various (white, Asian, black or other)	Paclitaxel	335	7.4	0.54	Ramucirumab + paclitaxel	330	9.6	0.59	0.006

¹Mean or median age with range in parenthesis;

²Calculated from confidence intervals according to the procedure described by Altman et al[13];

³The trial by Kang et al[4] included a third arm treated with irinotecan (N = 60) in which median OS was 7.9 mo (SE = 1.02 mo). OS: Overall survival; SE: Standard error; N: Number of patients; BSC: Best supportive care.